Aurinia (AUPH) reported 48-week data from its AURA-LV study. At the National Kidney Foundation 2017 spring clinical meetings, the company reported continued improvements in renal and extra-renal outcomes. All of the patients in complete remission at week 24 stay so at week 48. Renal function is stable as subjects take low-dose voclosporin.AUPH stock, range-bound between $2 - $5 up until February, is a speculation. Expect volatility spiking in the days ahead.Source of PR. Efficacy results are in the table below: Endpoint Treatment 24 weeks P-value* 48 weeks P-value* Complete Remission (CR) 23.7mg VCS BID 33% p=.045 49% p<.001 39.5mg VCS BID 27% p=.204 40% p=.026 Control Arm 19% NA 24% NA Partial Remission (PR) 23.7mg VCS BID 70% p=.007 69% p=.007 39.5mg VCS BID 66% p=.024 72% p=.002 Control Arm 49% NA 48% NA Time to CR (TTCR) [median] 23.7mg VCS BID 19.7 weeks p<.001 19.7 weeks p<.001 39.5mg VCS BID 23.4 weeks p=.001 23.4 weeks p<.001 Control Arm NA NA NA NA Time to PR (TTPR) [median] 23.7mg VCS BID 4.1 weeks p=.002 4.3 weeks p=.005 39.5mg VCS BID 4.4 weeks P=.003 4.4 weeks p=.002 Control Arm 6.6 weeks NA 6.6 weeks NA SLEDAI Reduction (non-renal lupus) 23.7mg VCS BID -6.3 p=.003 -7.9 p<.001 39.5mg VCS BID -7.1 p=.003 -8.3 p<.001 Control Arm -4.5 NA -5.3 NA Reduction in UPCR 23.7mg VCS BID -3.769 mg/mg p<.001 -3.998 mg/mg p<.001 39.5mg VCS BID -2.792 mg/mg p=.006 -2.993 mg/mg p=.008 Control Arm -2.216 mg/mg NA -2.384 mg/mg NA *All p-values are vs control